CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade AcelRx - ACRX CFD

    0.6589
    5.73%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0355
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 0.01
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    AcelRx Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.6978
    Open* 0.7079
    1-Year Change* 202.78%
    Day's Range* 0.6478 - 0.7179
    52 wk Range 0.16-0.95
    Average Volume (10 days) 589.82K
    Average Volume (3 months) 46.02M
    Market Cap 31.41M
    P/E Ratio 0.74
    Shares Outstanding 147.33M
    Revenue 2.88M
    EPS 0.29
    Dividend (Yield %) N/A
    Beta 0.45
    Next Earnings Date Nov 14, 2022

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 22, 2023 0.6578 -0.0501 -7.08% 0.7079 0.7180 0.6478
    Sep 21, 2023 0.6978 -0.0500 -6.69% 0.7478 0.7578 0.6496
    Sep 20, 2023 0.7398 -0.0380 -4.89% 0.7778 0.8305 0.7398
    Sep 19, 2023 0.7977 -0.0251 -3.05% 0.8228 0.8278 0.7678
    Sep 18, 2023 0.8227 -0.0551 -6.28% 0.8778 0.9128 0.7988
    Sep 15, 2023 0.8878 0.0000 0.00% 0.8878 0.8979 0.8503
    Sep 14, 2023 0.8878 0.0900 11.28% 0.7978 0.8978 0.7878
    Sep 13, 2023 0.8364 -0.0483 -5.46% 0.8847 0.8982 0.8078
    Sep 12, 2023 0.8693 0.0815 10.35% 0.7878 0.9079 0.7878
    Sep 11, 2023 0.7779 -0.0899 -10.36% 0.8678 0.8678 0.7642
    Sep 8, 2023 0.8481 0.0020 0.24% 0.8461 0.8847 0.8461
    Sep 7, 2023 0.8761 -0.0703 -7.43% 0.9464 0.9464 0.8461
    Sep 6, 2023 0.9252 -0.0391 -4.05% 0.9643 0.9643 0.8962
    Sep 5, 2023 0.9661 -0.0500 -4.92% 1.0161 1.0461 0.9367
    Sep 1, 2023 1.0261 0.0000 0.00% 1.0261 1.0461 0.9648
    Aug 31, 2023 1.0261 0.0300 3.01% 0.9961 1.0761 0.9961
    Aug 30, 2023 1.0261 0.1100 12.01% 0.9161 1.0261 0.9111
    Aug 29, 2023 0.9501 0.0615 6.92% 0.8886 0.9861 0.8461
    Aug 28, 2023 0.9161 -0.1000 -9.84% 1.0161 1.0561 0.8204
    Aug 25, 2023 1.0861 -0.0200 -1.81% 1.1061 1.1061 1.0261

    AcelRx Events

    Time (UTC) Country Event
    Tuesday, October 10, 2023

    Time (UTC)

    17:00

    Country

    US

    Event

    AcelRx Pharmaceuticals Inc Annual Shareholders Meeting
    AcelRx Pharmaceuticals Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Monday, November 13, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 AcelRx Pharmaceuticals Inc Earnings Release
    Q3 2023 AcelRx Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total revenue 2.818 5.416 2.289 2.151 7.995
    Revenue 2.818 5.416 2.289 2.151 7.995
    Cost of Revenue, Total 3.753 6.032 6.806 3.976 10.659
    Gross Profit -0.935 -0.616 -4.517 -1.825 -2.664
    Total Operating Expense 38.783 46.379 56.494 37.878 46.677
    Selling/General/Admin. Expenses, Total 30.935 36.33 45.027 20.765 16.609
    Research & Development 4.095 4.017 4.661 13.137 19.409
    Unusual Expense (Income) 0
    Operating Income -35.965 -40.963 -54.205 -35.727 -38.682
    Interest Income (Expense), Net Non-Operating -2.167 -2.722 -0.369 -1.079 -2.806
    Other, Net 3.038 3.31 1.337 -10.341 -10.721
    Net Income Before Taxes -35.094 -40.375 -53.237 -47.147 -52.209
    Net Income After Taxes -35.099 -40.379 -53.24 -47.149 -17.405
    Net Income Before Extra. Items -35.099 -40.379 -53.24 -47.149 -17.405
    Net Income -35.099 -40.379 -53.24 -47.149 -51.508
    Income Available to Common Excl. Extra. Items -35.099 -40.379 -53.24 -47.149 -17.405
    Income Available to Common Incl. Extra. Items -35.099 -40.379 -53.24 -47.149 -51.508
    Diluted Net Income -35.099 -40.379 -53.24 -47.149 -51.508
    Diluted Weighted Average Shares 119.86 85.257 79.1843 58.4086 46.8835
    Diluted EPS Excluding Extraordinary Items -0.29283 -0.47362 -0.67236 -0.80723 -0.37124
    Diluted Normalized EPS -0.29387 -0.47362 -0.67236 -0.80723 -0.37124
    Total Extraordinary Items 0 -34.103
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total revenue 0.442 0.002 1.862 0.443 0.511
    Revenue 0.442 0.002 1.862 0.443 0.511
    Cost of Revenue, Total 0.784 1.234 0.439 1.04 1.04
    Gross Profit -0.342 -1.232 1.423 -0.597 -0.529
    Total Operating Expense 9.437 8.177 10.495 10.458 9.653
    Selling/General/Admin. Expenses, Total 7.338 5.957 8.64 8.694 7.644
    Research & Development 1.315 0.986 1.416 0.724 0.969
    Operating Income -8.995 -8.175 -8.633 -10.015 -9.142
    Interest Income (Expense), Net Non-Operating -0.352 -0.435 -0.506 -0.63 -0.596
    Other, Net 0.673 0.693 0.764 0.799 0.782
    Net Income Before Taxes -8.674 -7.917 -8.375 -9.846 -8.956
    Net Income After Taxes -8.674 -7.917 -8.375 -9.851 -8.956
    Net Income Before Extra. Items -8.674 -7.917 -8.375 -9.851 -8.956
    Net Income -8.674 -7.917 -8.375 -9.851 -8.956
    Income Available to Common Excl. Extra. Items -8.674 -7.917 -8.375 -9.851 -8.956
    Income Available to Common Incl. Extra. Items -8.674 -7.917 -8.375 -9.851 -8.956
    Diluted Net Income -8.674 -7.917 -8.375 -9.851 -8.956
    Diluted Weighted Average Shares 145.624 127.774 119.224 119.12 113.257
    Diluted EPS Excluding Extraordinary Items -0.05956 -0.06196 -0.07025 -0.0827 -0.07908
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.05956 -0.06196 -0.07025 -0.08089 -0.08369
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total Current Assets 55.489 46.83 71.688 107.994 63.413
    Cash and Short Term Investments 51.63 42.886 66.137 105.715 60.469
    Cash & Equivalents 12.663 27.274 14.684 87.975 52.902
    Short Term Investments 38.967 15.612 51.453 17.74 7.567
    Total Receivables, Net 0.16 0.635 0.52 0.401 1.533
    Accounts Receivable - Trade, Net 0.16 0.635 0.432 0.049 1.533
    Total Inventory 1.111 1.626 3.295 0.854 0.956
    Prepaid Expenses 2.588 1.683 1.736 1.024 0.455
    Total Assets 77.893 66.295 91.356 120.533 75.552
    Property/Plant/Equipment, Total - Net 20.23 18.809 18.48 11.483 11.051
    Property/Plant/Equipment, Total - Gross 31.016 29.398 28.032 20.427 19.489
    Accumulated Depreciation, Total -10.786 -10.589 -9.552 -8.944 -8.438
    Other Long Term Assets, Total 2.174 0.656 0.925 0.705 0.385
    Total Current Liabilities 18.509 17.635 13.611 15.928 13.66
    Accounts Payable 2.121 2.737 1.72 2.07 1.424
    Accrued Expenses 7.506 6.008 6.498 4.54 3.543
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 8.796 8.841 4.982 9.003 8.331
    Other Current Liabilities, Total 0.086 0.049 0.411 0.315 0.362
    Total Liabilities 113.786 122.045 132.774 116.28 112.061
    Total Long Term Debt 5.007 13.14 20.517 3.38 11.369
    Long Term Debt 5.007 13.14 20.517 3.38 11.369
    Other Liabilities, Total 90.27 91.27 98.646 96.972 87.032
    Total Equity -35.893 -55.75 -41.418 4.253 -36.509
    Common Stock 0.137 0.098 0.079 0.078 0.051
    Additional Paid-In Capital 437.554 382.637 356.609 349.194 261.31
    Retained Earnings (Accumulated Deficit) -473.584 -438.485 -398.106 -345.019 -297.87
    Other Equity, Total 0
    Total Liabilities & Shareholders’ Equity 77.893 66.295 91.356 120.533 75.552
    Total Common Shares Outstanding 136.82 98.812 79.5731 78.7579 50.8992
    Note Receivable - Long Term 0.263 0.351 0.703
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total Current Assets 42.811 55.489 51.753 58.97 71.315
    Cash and Short Term Investments 39.349 51.63 48.699 55.325 67.345
    Cash & Equivalents 21.822 12.663 13.271 26.327 34.363
    Short Term Investments 17.527 38.967 35.428 28.998 32.982
    Total Receivables, Net 0.184 0.16 0.153 0.104 0.658
    Accounts Receivable - Trade, Net 0.184 0.16 0.153 0.104 0.658
    Total Inventory 1.045 1.111 1.556 1.363 1.419
    Prepaid Expenses 2.233 2.588 1.345 2.178 1.893
    Total Assets 71.971 77.893 72.263 79.586 87.347
    Property/Plant/Equipment, Total - Net 20.08 20.23 20.229 20.546 15.962
    Other Long Term Assets, Total 0.261 2.174 0.281 0.07 0.07
    Total Current Liabilities 17.033 18.509 17.07 15.188 15.544
    Accounts Payable 2.715 2.121 2.228 1.941 3.235
    Accrued Expenses 5.505 7.592 6.062 4.483 3.528
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 8.813 8.796 8.78 8.764 8.781
    Other Current Liabilities, Total 0
    Total Liabilities 110.244 113.786 115.284 115.575 114.659
    Total Long Term Debt 3.041 5.007 6.952 9.374 11.265
    Long Term Debt 3.041 5.007 6.952 9.374 11.265
    Other Liabilities, Total 90.17 90.27 91.262 91.013 87.85
    Total Equity -38.273 -35.893 -43.021 -35.989 -27.312
    Common Stock 0.147 0.137 0.119 0.119 0.118
    Additional Paid-In Capital 443.838 437.554 422.527 421.184 420.011
    Retained Earnings (Accumulated Deficit) -482.258 -473.584 -465.667 -457.292 -447.441
    Total Liabilities & Shareholders’ Equity 71.971 77.893 72.263 79.586 87.347
    Total Common Shares Outstanding 147.109 136.82 119.317 119.18 119.103
    Intangibles, Net 8.819
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Net income/Starting Line -35.099 -40.379 -53.24 -47.149 -51.508
    Cash From Operating Activities -30.002 -38.505 -51.18 -29.075 -29.765
    Cash From Operating Activities 1.973 1.853 1.668 0.575 1.744
    Non-Cash Items 2.921 2.309 4.298 15.632 16.3
    Cash Taxes Paid 0.005 -0.347 -0.35 0.002 0.002
    Cash Interest Paid 1.595 2.269 1.712 1.667 2.043
    Changes in Working Capital 0.203 -2.288 -3.906 1.867 3.699
    Cash From Investing Activities -26.123 34.139 -36.563 -10.877 -9.97
    Capital Expenditures -1.827 -1.855 -3.47 -0.819 -2.405
    Other Investing Cash Flow Items, Total -24.296 35.994 -33.093 -10.058 -7.565
    Cash From Financing Activities 41.514 16.956 14.452 75.025 12.327
    Financing Cash Flow Items 5.313 -0.086 -9.054 0 -0.204
    Issuance (Retirement) of Stock, Net 45.034 21.709 1.976 82.743 16.045
    Issuance (Retirement) of Debt, Net -8.833 -4.667 21.53 -7.718 -3.514
    Net Change in Cash -14.611 12.59 -73.291 35.073 -27.408
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Net income/Starting Line -8.674 -35.099 -27.182 -18.807 -8.956
    Cash From Operating Activities -8.934 -30.002 -21.998 -18.055 -9.708
    Cash From Operating Activities 0.42 1.973 1.512 1.029 0.45
    Non-Cash Items 0.246 2.921 1.75 0.966 0.03
    Changes in Working Capital -0.926 0.203 1.922 -1.243 -1.232
    Cash From Investing Activities 20.176 -26.123 -21.684 -15.032 -17.425
    Capital Expenditures -0.089 -1.827 -1.799 -1.615 -0.024
    Other Investing Cash Flow Items, Total 20.265 -24.296 -19.885 -13.417 -17.401
    Cash From Financing Activities -2.083 41.514 29.679 32.14 34.222
    Financing Cash Flow Items -0.058 5.313 -0.249 -0.249 -0.249
    Issuance (Retirement) of Stock, Net 0.058 45.034 36.678 36.556 36.554
    Issuance (Retirement) of Debt, Net -2.083 -8.833 -6.75 -4.167 -2.083
    Net Change in Cash 9.159 -14.611 -14.003 -0.947 7.089

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    AcelRx Company profile

    AcelRx
    Industry: Bio Therapeutic Drugs

    25821 Industrial Boulevard
    Suite 400
    94545

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    Oil - Crude

    90.14 Price
    +0.770% 1D Chg, %
    Long position overnight fee 0.0415%
    Short position overnight fee -0.0634%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    ETH/USD

    1,596.49 Price
    +0.120% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    BTC/USD

    26,624.10 Price
    +0.150% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    XRP/USD

    0.51 Price
    -0.840% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading